Research

font size decrease font size increase font size
Print
Email

Clinuvel has conducted over 15 trials of SCENESSE® (afamelanotide) in over 600 patients, published research from which can be purchased online.

Below is a selection of published research on SCENESSE®.

Haylett AK, Nie Z, Brownrigg M, Taylor R, E Rhodes L, (2010). "Systemic photoprotection in solar urticaria with α-melanocyte stimulating hormone analogue [Nle(4) -D-Phe(7) ]-α-MSH." Br J Dermatol. Oct 22 [Epub ahead of print].
Minder, EI (2010). "Afamelanotide". Drugs of the Future. 35(5): 365.
Harms JH, Lautenschlager S, Minder CE, Minder EI, (2009). “Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.” Photochem Photobiol 85(6):1434-9.
Harms, J et al., 2009, ‘An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria’, New England Journal of Medicine, 360(3):306-307.
Barnetson R, et al, (2006). “[Nle⁴-D-Phe⁷]-alpha-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers.” Journal of Investigative Dermatology 126, 1869–1878.
Hadley ME, Dorr RT, (2006). “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides 27(4):921-30. Epub 2006 Jan 18.
Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM, (2006). “Effect of [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.” Peptides 27(2):388-94. Epub 2005 Nov 15.
Dorr RT, et al, (2000). “Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.” Photochem Photobiol 72(4):526-32.
Levine N, et al (1999). “Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study.” Journal of Dermatological Treatment 10(2):127-32.

The links above direct you to sites outside of the control of Clinuvel which are not produced or endorsed by Clinuvel.

Over 200 articles have been published on afamelanotide (chemical name [Nle⁴, D-Phe⁷]α-MSH or NDP-MSH).

Tagged under

SCENESSE® Spotlight

SCENESSE® as a repigmentation therapy

Clinuvel is currently conducting two clinical trials to evaluate the efficacy of SCENESSE® as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy compared to NB-UVB alone. The goal of these trials is to determine whether SCENESSE® will reduce the total dose of radiation (NB-UVB) and the time required to reactivate skin pigment producing cells in ...